Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays
Sponsor: Barbara Ann Karmanos Cancer Institute
A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Barbara Ann Karmanos Cancer Institute and has accumulated 9 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2023 [monthly]
Completed PHASE2
-
Mar 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .